Advancements in Nanoparticle-Based Targeted Drug Delivery Systems for Breast Cancer

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Breast cancer is a significant global health concern, with chemotherapy causing severe side effects due to its non-specific action.
• Current treatment options for breast cancer vary by stage (0-IV) but often lack specificity.
• There is a critical need for advanced therapeutic strategies to improve treatment efficacy and minimize harm to healthy tissues.

Purpose of the Study:

• To review modified nano-sized carriers for targeted breast cancer drug delivery.
• To explore the mechanisms of ligand-mediated nanocarrier systems for enhanced therapeutic outcomes.
• To discuss the potential of advanced nanocarriers in overcoming current breast cancer treatment limitations.

Main Methods:

• Review of literature on modified nanocarriers, including liposomes, micelles, polymeric nanocarriers, carbon dots, and gold nanoparticles.
• Analysis of active targeting strategies based on ligand-receptor interactions for tumor-specific delivery.
• Examination of mechanisms to improve therapeutic efficacy, bioavailability, and pharmacokinetics.

Main Results:

• Modified nanocarriers demonstrate potential for enhanced tumor-specific drug delivery via active targeting.
• Ligand-mediated systems can improve therapeutic efficacy and reduce systemic toxicity compared to passive targeting.
• Various nanocarrier platforms show promise in optimizing drug delivery for different breast cancer stages and types.

Conclusions:

• Advanced nanocarriers, particularly those employing ligand-mediated targeting, represent a promising frontier in breast cancer therapy.
• Surface modification of nanocarriers is key to achieving precise cancer targeting and improved treatment outcomes.
• Further research into these nanocarrier systems can lead to more effective and safer breast cancer treatments.